Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...
Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause ...
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...
In April, a former district parent sued Lake Travis ISD after two of her son's teammates on the Lake Travis High School team ...
Nvidia helped pull U.S. stock indexes higher after they stumbled in the morning on worries about escalations in the ...
Incyte shares slid after the drug maker paused trial enrollment for a hives treatment, and discontinued development of another treatment for a skin condition. Spanish drug maker Grifols said its board ...
Research suggests the popular spice is highly effective for those with cholesterol, arthritis and high blood sugar ...
Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...
Amcor slipped 0.3 per cent. Loading Incyte tumbled 11.1 per cent after the biopharmaceutical company said it’s pausing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback